Paclitaxel for Anal Squamous Cell Carcinoma (Metastatic)

Phase-Based Progress Estimates
Anal Squamous Cell Carcinoma (Metastatic)+9 MorePaclitaxel - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing nivolumab in combination with carboplatin and paclitaxel versus the usual treatment of carboplatin and paclitaxel for anal cancer that has spread to other parts of the body.

Eligible Conditions
  • Anal Squamous Cell Carcinoma (Metastatic)
  • Stage IIIA Anal Cancer
  • Stage IIIC Anal Cancer
  • Stage IIIB Anal Cancer
  • Unresectable Anal Squamous Cell Carcinoma
  • Stage III Anal Cancer
  • Stage IV Anal Cancer
  • Anal Basaloid Carcinoma
  • Anal Squamous Cell Carcinoma
  • Anal Canal Cloacogenic Carcinoma

Video Summary

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to 2 years

Year 2
Overall survival
Up to 2 years
Incidence of adverse events
Objective response rate (ORR)
Progression-free survival

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Arm A (carboplatin, paclitaxel)
1 of 2
Arm B (carboplatin, paclitaxel, nivolumab)
1 of 2

Active Control

Experimental Treatment

205 Total Participants · 2 Treatment Groups

Primary Treatment: Paclitaxel · No Placebo Group · Phase 3

Arm B (carboplatin, paclitaxel, nivolumab)Experimental Group · 3 Interventions: Paclitaxel, Nivolumab, Carboplatin · Intervention Types: Drug, Biological, Drug
Arm A (carboplatin, paclitaxel)ActiveComparator Group · 2 Interventions: Paclitaxel, Carboplatin · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,084 Previous Clinical Trials
41,141,439 Total Patients Enrolled
Cathy EngPrincipal InvestigatorECOG-ACRIN Cancer Research Group
3 Previous Clinical Trials
238 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a hemoglobin level of at least 9 g/dL for males and at least 9 g/dL for females.
You have inoperable, recurrent, or metastatic disease not amenable to curative therapy.
Patient must have histological or cytological confirmation of anal squamous cell carcinoma (includes basaloid and cloacogenic lesions) from the primary tumor or a newly diagnosed recurrent/metastatic lesion.
You are eligible if you are at least 18 years of age.
Patient must have Eastern Cooperative Oncology Group (ECOG) performance status =< 0-1.
Patients must have measurable disease according to RECIST criteria version 1.1 and based on radiologic assessment performed < 4 weeks prior to randomization.
Patients with untreated brain metastases are eligible if they are asymptomatic and if treatment ended > 3 months prior to randomization.
You have a neutrophil count of at least 1,500/mcL.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
Kaiser Permanente-San Francisco100.0%
What portion of applicants met pre-screening criteria?
Met criteria50.0%
Did not meet criteria50.0%